Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
4.9.2023 08:38:00 EEST | Business Wire | Press release
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®. The transaction was closed upon signing.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. The difficulty of avoiding peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for effective treatment3.
“We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer. “Palforzia®, with its robust efficacy and safety profile, is currently the only available approved treatment for inadvertent exposure to peanuts. By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer. There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
With this transaction, Stallergenes Greer further strengthens its presence in the field of AIT. The company’s portfolio offers patients and healthcare professionals precise personalised AIT treatments which cover a broad range of administration modes and can be tailored to the individual needs of patients with allergies: sublingual oral solutions, tablets, and injectables for respiratory allergies; and powder to be consumed with semi-solid foods for peanut allergies.
ABOUT PALFORZIA ®
Palforzia® is an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic. Use of Palforzia® may be continued in patients 18 years of age and older.
Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/. Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903080283/en/
Contact information
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM to Drive AI-Powered Modernization of IT Infrastructure and Application Support for UK-based SSP Group26.5.2026 12:00:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has entered a strategic partnership with SSP Group, a leading operator of food and beverage outlets in travel locations worldwide. Through this AI-powered partnership, LTM will deliver modernized, end-to-end IT infrastructure support and enhanced application maintenance services to SSP Group. As part of this engagement, LTM will leverage its advanced AI capabilities including its BlueVerseTM ecosystem to help SSP manage operational risks, simplify infrastructure and application complexities, and drive business efficiency and agility. Additionally, the collaboration will focus on enabling data-driven decision-making, accelerating innovation through automation, delivering scalable solutions that enhance customer experience, and driving cost optimization through AI automation and simplification. “As we continue to advance our IT capabilities, having a trusted partner like LTM with deep domain expertise and a focus on
ROYC and Stilla Enter Strategic Partnership to Operationalise Agentic AI in Private Markets26.5.2026 11:30:00 EEST | Press release
ROYC today announced a partnership with Stilla.ai as the platform layer where ROYC will create, share and run its internally developed AI skills and agents. This operationalises the agentic AI strategy ROYC set out earlier, equipping every function across the company with the tools and resources to build and deploy their own AI agents and converting this into measurable productivity gains and accelerated product development. This will substantially accelerate launch of new platform features, improving cost efficiency at the same time as strengthening overall governance and oversight. For ROYC’s customers and partners, the result will be shorter time-to-market for new product releases, shorter time frames moving from idea to productification and tailored customer experience from an investor services perspective. “Our strategy is clear: AI is embedded in every aspect of our ways of working and what the ROYC Operating System does, not a side project,” said Peter Bergenwald, CTO of ROYC. “
IQOS One of the Most Valuable Global Brands, According to Kantar’s BrandZ 2026 Ranking26.5.2026 11:00:00 EEST | Press release
Philip Morris International’s (PMI) (NYSE: PM) IQOS, the #1 tobacco heating system1, has been listed for the first time as one of the top 100 most valuable brands in the world in Kantar’s BrandZ 2026 Most Valuable Global Brands. This ranking solidifies IQOS’s global momentum and its emergence as a culturally relevant, iconic brand for adult nicotine users seeking better alternatives to cigarettes. According to the BrandZ 2026 Most Valuable Global Brands, IQOS achieved a ranking of #74 globally. With more than 35 million IQOS users worldwide—most of whom have fully switched away from cigarettes2—the brand continues to lead from the front and champion in a smoke-free era through science-backed innovation and consumer-centric design. Within 10 years of inception, IQOS surpassed $10 billion in annual net revenues, reaching this milestone faster than some of the world’s most recognized technology companies—and making up the large majority of Philip Morris International’s smoke-free business
Quectel Expands EMEA Reach With Future Electronics Distribution Agreement26.5.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced an expanded distribution partnership with Future Electronics to bring its full portfolio of products and services to customers across the EMEA region. Under this agreement, Future Electronics will bring Quectel’s full IoT portfolio to customers across Europe, the Middle East and Africa, with a strong focus on its non-cellular solutions, including antennas, GNSS, Wi-Fi, Bluetooth and smart modules. This collaboration marks a significant step in strengthening Quectel’s presence in EMEA, leveraging Future Electronics’ strong regional infrastructure, technical expertise, and established customer relationships to accelerate growth and innovation. “Future Electronics’ extensive footprint and demand creation capabilities make them an ideal partner for expanding our reach across EMEA,” said Natasha Barrios, Senior Vice President, EMEA, Quectel Wireless Solutions. “By working together, we can ensure faster a
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 10:00:00 EEST | Press release
Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization in the licensed territory under a jointly agreed China Development Plan. Merz will act as Overseas Holder of the Drug Registration Certificate and Kvvit will serve as Domestic Responsible Person, funding local clinical development and regulatory submissions. INBRIJA® is currently not approved in China, Hong Kong and Macao
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom